Fosun holds 5 top explosives, 72 innovative drugs and 18 biosimilar drugs

Pharmanet News, August 27 After the pharmaceutical sector has undergone a round of policy baptism, Fosun Pharma’s 2021 interim results released by Fosun Pharma has aroused many investors’ eyes
.
In 2021H1, the company achieved a net profit of 2.
482 billion yuan, a year-on-year increase of 44.
77%
.
The revenue of core anti-tumor and immunomodulation products increased by 256.
69% year-on-year .
As an established pharmaceutical company, Fosun Pharma's generic drugs are also facing the impact of centralized procurement, and innovative products have become a strong "blood transfusion" support
.
The company continues to focus on innovation and internationalization, with 72 innovative drugs under research, 18 biosimilar drugs, 5 innovative products including PD-1 monoclonal antibody and Parkinson's drugs have been reported for production, and many products are in clinical phase III Stage
.
Heavy varieties soared 223.
21% ! Half year net profit of 24.
82 Yithe first half of 2021, Fosun Pharmaceutical to achieve operating income of 16.
952 billion yuan, an increase of 20.
85%; net profit of 2.
482 billion yuan, an increase of 44.
77%
.
  　　Net profit of Fosun Pharma (unit: 100 million yuan) Fosun Pharma is based in China and expands its global business.
Its direct operations include pharmaceuticals, medical devices and medical diagnosis, and medical and health services.
It also covers the pharmaceutical business through equity participation in Sinopharm Holdings Field
.
Among them, the pharmaceutical business is the company's main source of revenue, with 12.
248 billion yuan in revenue in the first half of the year, accounting for 72.
25% of revenue; medical equipment, medical diagnosis, and medical health services accounted for 16.
74% and 10.
88% of revenue in the first half of the year
.
As a veteran pharmaceutical company, Fosun Pharma’s stock of generic drugs is also facing the impact of centralized procurement.
The company’s existing varieties such as Ulitong (febuxostat tablets) and Bangzhi (pitavastatin calcium tablets) are included in centralized procurement, and their sales prices have fallen.
Brought about a decline in sales revenue
.
In the first half of the year, the company's sales revenue of core products in the treatment of metabolism and digestive system, central nervous system, and cardiovascular system decreased by 19.
92%, 18.
41%, and 17.
95% respectively year-on-year
.
  　　Sales revenue of core products in Fosun Pharma's main therapeutic areas Thanks to the continuous implementation of innovative achievements, the increase in sales of innovative products has made up for the reduction in revenue from centralized procurement products and has promoted the sustainable growth of the company's performance
.
In the first half of the year, the sales revenue of Fosun Pharma's anti-tumor and immunomodulation core products increased by 256.
69% year-on-year, mainly due to the significant increase in sales of Han Likang (rituximab injection).
The cumulative revenue in the first half of the year was 724 million yuan, an increase of 223.
21% year-on-year; Han Quyou (trastuzumab for injection) and Su Kexin (avatropol maleate tablets), which were launched in the second half of 2020, achieved revenues of 325 million yuan and 206 million yuan respectively in the first half of the year
.
In the first half of the year, the company's anti-infective core product sales revenue increased by 45.
30% year-on-year, mainly due to the revenue contribution of Fubitai (mRNA new crown vaccine) and the sales revenue growth of micafungin
.
Among them, Fubitai (mRNA new crown vaccine) was included in the government vaccination plan in Hong Kong and Macau in the first half of the year, and achieved revenue of more than 500 million yuan during the reporting period
.
  　　Holding 5 major explosives, 72 innovative drugs and 18 biosimilar drugs on the road,   　　"innovation" and "internationalization" have become the distinctive labels of Fosun Pharma
.
With its pharmaceutical business as its core, Fosun Pharma insists on innovative research and development.
Through independent research and development, cooperative development, license introduction, and in-depth incubation, it focuses on tumor and immune regulation, four highs (hypertension, hyperlipidemia, hyperglycemia, hyperuricemia) Establish and form technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy in key disease areas such as complications and central nervous system, and actively explore cutting-edge technology fields such as targeted protein degradation, RNA, oncolytic viruses, and gene therapy to enhance innovation ability
.
In the first half of 2021, Fosun Pharma’s R&D investment in its pharmaceutical business was RMB 1.
77 billion, a year-on-year increase of 15.
31%.
The pharmaceutical business R&D investment accounted for 14.
51% of its pharmaceutical business revenue
.
Among them, R&D expenses were 1.
385 billion yuan, an increase of 326 million yuan or 30.
78% year-on-year, accounting for 11.
31% of pharmaceutical business revenue
.
  　　Research and development expenses of Fosun Pharma's pharmaceutical business (unit: 100 million yuan) It is worth mentioning that in recent years, the research and development expenses of Fosun Pharma's pharmaceutical business have maintained high growth
.
With huge R&D expenditures, the company has also harvested a number of blockbuster products, and the high volume of innovative products has promoted sustainable growth in performance
.
There are currently 5 key innovative products of Fosun Pharma, including rituximab injection, trastuzumab for injection, avatropol maleate tablets, adalimumab injection and akirensex Injection
.
Among them, rituximab injection is the first biosimilar drug in China; trastuzumab for injection is the first biosimilar drug of trastuzumab in China; avatropol maleate is the first in the world Approved oral drugs for the treatment of chronic liver disease-related thrombocytopenia, filling the domestic gap; Akirensai injection is the first CAR-T cell therapy product in China
.
  　　Fosun Pharma’s key domestic marketed products As of the end of the reporting period, Fosun Pharma’s main research projects for innovative drugs, generic drugs, biosimilars, and generic drugs consisted of 240 items, including 30 small molecule innovative drugs and 29 bio-innovative drugs.
There are 13 innovative drugs, 18 biosimilar drugs, 103 generic drugs, and 38 consistency evaluation projects
.
Among them, 5 products have been submitted for marketing applications, including slulimumab injection (PD-1 monoclonal antibody), bevacizumab injection, Parkinson's drug opicapone capsules, insulin glargine, and recombinant lispro insulin
.
In addition, a number of product developments are in clinical phase III, including ferric citrate pyrophosphate solution, Tenapanor tablets, RT002, protamine zinc recombinant insulin lispro mixed injection (50R), liraglutide injection, recombinant human booster Red element injection (CHO cells) and so on
.
  　　Fosun Pharma’s application for marketing has been reviewed for 　39 varieties of products   　, and 19 varieties have won the bid for centralized procurement.
The   　　country’s centralized procurement has carried out five batches and six rounds, and a total of 218 varieties have been included
.
Centralized procurement is the fate of generic drugs, and the reduction of profits of traditional generic drugs is an unavoidable challenge for leading domestic pharmaceutical companies
.
Under the impact of the normalization of centralized procurement, the "Innovative Drug One Brother" was also beaten back to the prototype, the market value fell sharply, and the stock price went down
.
Fosun Pharma’s stock of generic drugs has also been impacted by centralized procurement.
How has the company responded? According to data from Meinenet, Fosun Pharma has passed/deemedly passed the consistency evaluation of 39 varieties (58 acceptance numbers) of Fosun Pharma, of which 16 varieties were the first to have passed the evaluation.
Five varieties including Mitriptyline Tablets, Venlafaxine Hydrochloride Tablets and Potassium Chloride Granules are temporarily reviewed exclusively
.
From the perspective of the treatment field, the number of systemic anti-infective drugs and neurological drugs has the largest number of reviews, with 10 and 8 drugs respectively
.
Among the five batches of drugs purchased in a centralized manner, Fosun Pharma won the bids for 2, 4, 5, 6 and 2 varieties respectively, and a total of 19 varieties won the bids
.
It is worth noting that the 19 bid-winning varieties are mainly stock varieties, of which the unit prices of febuxostat tablets, quetiapine fumarate tablets, pitavastatin calcium tablets and other products have fallen after the implementation of centralized procurement
.
For the stock varieties included in centralized procurement, Fosun Pharma takes advantage of multi-channel marketing and refined production to strengthen the life cycle management of centralized procurement products while exchanging price for volume, and at the same time actively promotes incremental products to quickly enter the market through centralized procurement.
, Effectively smooth the impact of existing product purchases
.
  　　Fosun Pharma’s centralized procurement of selected products.
  　　Concluding remarks   　　In recent years, national medical reform policies have been frequently issued.
As an “all-rounder” player in the pharmaceutical and medical industry, Fosun Pharma has faced multiple challenges, such as key monitoring, centralized procurement of generic drugs, medical insurance negotiations, etc.
It is gratifying It is the company's early deployment of products that ushered in the harvest period, and gained strong "blood transfusion" support through innovative products
.
At the same time, by virtue of the layout of the new crown vaccine and the medical beauty track, Fosun Pharma has stood out from the rest of the pharmaceutical stocks
.
The dividends of generic drugs have gradually faded, and a wave of industry innovation and transformation has emerged
.
Fosun Pharma has been running on the road of innovation for many years, and has very clear plans for the future, such as "building a US$5 billion blockbuster product" and "innovative drug business accounts for more than 50% of revenue
.
" Today, Fosun Pharma has pulled out the clouds and walked out of its own sky
.
It is believed that under the requirements of high standards, Fosun Pharma's innovative position will become more prominent
.
  　　Data source: Mi Nei.
com database, company announcement